A clinical trial recently has shown that the widely used and cost -effective drug metformin for type 2 diabetes can significantly reduce the knee osteoarthritis (OA) pain. This discovery provides hope for millions of victims from this degenerative joint position.
Study Highlights
The study published in the Journal of the American Medical Association included overweight or thick individuals with symptomatic knee OA. Participants receiving metformin over a period of six months reported a significant reduction in knee pain compared to a placebo.
Professor Flevia Sisutinian emphasized the possible impact of these findings: “Metformin can be a new and inexpensive way to improve knee pain. General physicians are very familiar with this low cost, safe medicine, which can be provided to patients with other treatments and delay in knee needs”.
Implications for Treatment
Traditionally, knee management includes nonsteroidal anti-inflammatory drugs (NSAID), physical therapy and, in severe cases, surgery. The introduction of metformin as a potential treatment can offer a safe, more accessible option, especially for patients who are not an ideal candidate for NSAID or surgical intervention.
Given its ability and installed safety profile, metformin can become a valuable additional for therapeutic options for knee OA. However, large -scale studies are necessary to confirm these findings and establish comprehensive treatment guidelines.
Conclusion
This study underlines the ability to reproduce existing drugs to address chronic conditions such as osteoarthritis of the knee. As the research progresses, metformin can emerge as a decisive component in the management of the knee, providing relief to the people affected by this weak state.
(DISCLAIMER: The views expressed are solely of the research basis. Indiagnostic shall not be responsible for any damage caused to any person/organization directly or indirectly).
Sources:







